Form 4: Catalyst Pharmaceuticals Director Acquires Shares Through Vesting of Restricted Stock Units

Patrick J. McEnany, a director at Catalyst Pharmaceuticals, acquired 3,533 shares of common stock through the vesting of restricted stock units.

Summary

• Patrick J. McEnany, Chairman of the Board of Directors at Catalyst Pharmaceuticals, acquired 3,533 shares of common stock on December 9, 2024.
• These shares were obtained through the vesting of restricted stock units.
• The restricted stock units vest in three equal tranches, with the first tranche vesting on December 8, 2024.
• The remaining tranches will vest on December 8, 2025 and December 8, 2026.
• The shares were delivered to Mr. McEnany on December 9, 2024, within sixty days of the vesting date.
• Following this transaction, Mr. McEnany directly owns 4,481,702 shares of common stock and 1,838,130 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally neutral to positive. The acquisition of shares by a director can be seen as a sign of confidence in the company.

Positives

• The vesting of restricted stock units aligns the director's interests with those of the shareholders.
• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to insider transactions, which is common in publicly traded companies. It reflects the standard practice of compensating executives and directors with equity-based awards.

Comparison to Industry Standards

• Equity-based compensation, such as restricted stock units, is a common practice among publicly traded pharmaceutical companies like Catalyst Pharmaceuticals.
• The vesting schedule of the restricted stock units, with tranches vesting over three years, is also a typical approach to incentivize long-term performance and retention.
• Similar filings are regularly made by directors and officers of companies like BioMarin Pharmaceutical Inc. (BMRN) and Vertex Pharmaceuticals Incorporated (VRTX) when they receive or dispose of company stock.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Catalyst Pharmaceuticals, insider trading, stock acquisition, restricted stock units, share vesting, Patrick J. McEnany, director, CPRX